dc.relation.references | 1. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease.
Science. 1949;109(2835):443. Doi: 10.1126/science.110.2865.543
2. Ministério da Saúde (BR). Portaria conjunta n.º 05, de 19 de fevereiro de 2018. Aprova
o Protocolo Clínico e Diretrizes Terapêuticas da Doença Falciforme. Brasília: Ministério
da Saúde [Internet]. 2018 [cited 2024 Apr 22]. Available from:
https://bvsms.saude.gov.br/bvs/saudelegis/sas/2018/poc0005_22_02_2018.html#:~:text
=Aprova%20o%20Protocolo%20Cl%C3%ADnico%20e%20Diretrizes%20Terap%C3
%AAuticas%20da%20Doen%C3%A7a%20Falciforme
3. Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA.
2022;328(1):57-68. Doi:10.1001/jama.2022.10233
4. O`Brien EC, Ali S, Chevassut T. Sickle cell disease: an update. Clin Med.
2022;22(3):218-20. Doi:10.7861/clinmed.2022-0143
5. Ingram VM. A specific chemical difference between the globins of normal human and
sickle-cell anaemia haemoglobin. Nature. 1956;13;178(4537):792-4. Doi:
10.1038/178792a0
6. Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of
vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol.
2020;11:2040620720955000. Doi:10.1177/2040620720955000
7. Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Atenção
Especializada Doença falciforme: úlceras: prevenção e tratamento [Internet]. Brasília:
Ministério da Saúde; 2012a [cited 2024 May 12]. Available from:
https://www.nupad.medicina.ufmg.br/wp-content/uploads/2016/12/Manual-DoencaFalciforme-Ulceras-tratamento-e-prevencao.pdf
8. Delaney KM, Axelrod KC, Buscetta A, Hassell KL, Adams-Graves PE, Seamon C, et
al. Leg ulcers in sickle cell disease: current patterns and practices. Hemoglobin.
2013;37(4):325-32. Doi:10.3109/03630269.2013.789968
9. Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Atenção
Hospitalar e de Urgência. Doença falciforme: enfermagem nas urgências e emergências:
a arte de cuidar [Internet]. Brasília: Ministério da Saúde; 2014 [cited 2024 May 22].
Available from: https://www.nupad.medicina.ufmg.br/wpcontent/uploads/2016/12/Enfermagem-nas-Urgencias-e-Emergencias-A-arte-decuidar.pdf
10. Neumayr LD, Hoppe CC, Brown C. Sickle cell disease: current treatment and
emerging therapies. Am J Manag Care [Internet]. 2019 [cited 2024 Mar 25];25(18):S335-
103
43. Available from: https://www.ajmc.com/view/sickle-cell-disease-current-treatmentand-emerging-therapies
11. Madu A, Madu K, Anigbogu I, Ugwu AO, Okwulehie VA, Ololo U, et al. Phenotypic
characterisation and associations of leg ulcers in adult sickle cell patients. Wound Repair
Regen. 2022;30(1):126-31. Doi:10.1111/wrr.12970
12. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a
comparison of six methods. Pain. 1986;27(1):117-26. Doi:10.1016/0304-3959(86)90228-
9
13. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann
Acad Med Singap [Internet]. 1994 [cited 2024 Oct 20].;23(2):129-38. Available from:
https://europepmc.org/article/med/8080219
14. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr
Scand. 1983;67(6):361-370. Doi:10.1111/j.1600-0447.1983.tb09716.x
15. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a
língua portuguesa e validação do questionário geral de avaliação de qualidade de vida
SF-36 (Brasil SF-36). Rev Bras Reumatol [Internet]. 1999 [cited 2024 July
15];39(3):143-50. Available from: https://toneurologiaufpr.wordpress.com/wpcontent/uploads/2013/03/questionc3a1rio-de-qualidade-de-vida-sf36-traduc3a7c3a3o-evalidac3a7c3a3o.pdf
16. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The PatientReported Outcomes Measurement Information System (PROMIS): Progress of an NIH
Roadmap Cooperative Group During Its First Two Years. Medical Care. 2007;45(5):S3-
S11. Doi: 10.1097/01.mlr.0000258615.42478.55
17. Pecker LH, Lanzkron S. Sickle cell disease. Ann Intern Med. 2021;174(1):ITC1-16.
Doi:10.7326/AITC202101190
18. Ministério da Saúde (BR). Secretaria de Atenção Especializada a Saúde.
Departamento de Atenção Especializada e Temática. Saúde Escolar na Doença
Falciforme: um olhar às crianças e adolescentes com doença falciforme [Internet].
Brasília: Editora do Ministério da Saúde; 2024 [cited 2025 Jan 10]. Available from:
https://seduc.se.gov.br/download/saude-escolar-na-doenca-falciforme-um-olhar-ascriancas-e-adolescentes-com-doenca-falciforme/
19. Ministério da Saúde (BR). Doença Falciforme: Conhecer para cuidar. Brasília:
Ministério da Saúde [Internet]. 2015 [cited 2024 Apr 22]. Available from:
https://telelab.aids.gov.br/moodle/pluginfile.php/39506/mod_resource/content/4/Doenca
%20Falciforme_SEM.pdf
104
20. Paiva MM, Gomes SC. Acometimentos auditivos em pacientes portadores da doença
falciforme. Rev Ft. 2023;27(127):1-15. Doi: 10.5281/zenodo.10066856
21. Ashorobi D, Ramsey A, Yarrarapu SNS, Bhatt R. Sickle Cell Trait. In: StatPearls.
Treasure Island (FL): StatPearls Publishing [Internet]. 2022 [cited 2024 Apr 22].
Available from: https://www.ncbi.nlm.nih.gov/books/NBK537130/
22. Thomson AM et al. GBD 2021 Sickle Cell Disease Collaborators. Global, regionaland
national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic
analysis from the Global Burden of Disease Study 2021. Lancet Haematol.
2023;10(8):e585-e599. Doi:10.1016/S2352-3026(23)00118-7
23. Accioly J. Anemia falciforme – apresentação de um caso com infantilismo [Internet].
Tertúlias Acadêmicas, Arquivo da Universidade da Bahia. Salvador: Faculdade de
Medicina da Bahia; 1947 [cited 2024 June 20];2:169-98. Available from:
https://periodicos.ufba.br/index.php/arqmedicina/article/view/56069/29697
24. World Health Organization – WHO. Sickle-cell anaemia. Report by the Secretariat
Fifty-ninth World Health Assembly A59/9 [Internet]. 2006 [cited 2024 June 20].
Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf
25. Cançado RD, Costa FF, Lobo C, Migliavaca CB, Falavigna M, Souza Filho HC, et al.
Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world
evidence. Blood Advances. 2023;7(15):3783-92.
Doi:10.1182/bloodadvances.2022008938
26. Instituto de Pesquisa Econômica Aplicada- IPEA (BR). Seção 04 - Os níveis de
escolaridade no setor público brasileiro [Internet]. Brasília: IPEA; 2017 [cited 2024 Apr
22]. Available from: https://www.ipea.gov.br/atlasestado/arquivos/rmd/4874-
conjunto4v10.html#:~:text=O%20n%C3%ADvel%201%20compreende%20as,compree
nde%20pessoas%20com%20alguma%20p%C3%B3s
27. Ministério da Saúde (BR). Secretaria de Atenção à Saúde. Departamento de Atenção
Especializada. Doença falciforme: condutas básicas para tratamento [Internet]. Brasília:
Ministério da Saúde; 2012b [cited 2024 Jun 22]. (Série B, Textos Básicos de Saúde).
Available from:
https://bvsms.saude.gov.br/bvs/publicacoes/doenca_falciforme_condutas_basicas.pdf
28. Instituto Brasileiro de Geografia e Estatística – IBGE. Censo Demográfico 2022:
Identificação étnico-racial da população, por sexo e idade: Resultados do universo
[Internet]. 2022 [cited 2024 Feb 15]. Available from:
https://censo2022.ibge.gov.br/panorama/indicadores.html?localidade=BR&tema=2
29. Silva WS, Oliveira RF, Ribeiro SB, Silva IB, Araújo EM, Baptista AF. Screening for
structural hemoglobin variants in Bahia, Brazil. Int J Environ Res Saúde Pública.
2016;13(2):225. Doi: 10.3390/ijerph13020225
105
30. Ramos LV, Araújo RPC. Perfil epidemiológico dos óbitos por doença falciforme no
estado da Bahia, Brasil (2013-2022). Anais do Congresso On-line Nacional de Saúde
Multidisciplinar (Conasmulti) - 3ª edição. Doi: 10.53524/lit.edt.978-65-84528-37-6/33
31. Braga JA. Medidas gerais no tratamento das doenças falciformes. Hematol Transfus
Cell Ther. 2007;29:233-38. Doi: 10.1590/S1516-84842007000300009
32. Pulte D, Riddick-Burden G, Ballas SK. Characteristics of “older old" patients with
sickle cell anemia who survived for more than 80 years. Blood. 2015;126(23):4599. Doi:
10.1182/blood.V126.23.4599.4599
33.Hamamy HA, Al-Allawi NA. Epidemiological profile of common
haemoglobinopathies in Arab countries. J Community Genet. 2013;4(2):147-67.
Doi:10.1007/s12687-012-0127-8
34. Laghdaf Sidi M, N'Diaye AM, Cheikh M, Heinhane MM. Sickle Cell Disease in
Mauritania: epidemiological, clinical and therapeutic aspects about 135 cases. Tunis Med
[Internet]. 2022 [cited 2024 Feb 12];100(4):313-22. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486954/
35. Junqueira LC, Carneiro J. Histologia básica I Junqueira & Carneiro. 12. ed. Rio de
Janeiro: Guanabara Koogan; 2013
36. Kumar V, Abbas AK, Aster JC. Robbins Patologia Básica. 10. ed. Rio de Janeiro:
Guanabara Koogan; 2018
37. Mandal AK, Mitra A, Das R. Sickle cell hemoglobin. Subcell biochem. 2020;94:297-
322. Doi:10.1007/978-3-030-41769-7_12
38. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu
Rev Pathol. 2019;14:263-92. Doi:10.1146/annurev-pathmechdis-012418-012838
39. Loggetto SR, Veríssimo MPA, Darrigo-Junior LG, Simões R, Bernardo WM, Braga
JAP. Guidelines on sickle cell disease: secondary stroke prevention in children and
adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
guidelines project: Associação Médica Brasileira - 2022. Hematol Transfus Cell Ther.
2022;44(2):246-55. Doi:10.1016/j.htct.2022.01.010
40. Felix AA, Helio MS, Ribeiro SBF. Aspectos epidemiológicos e sociais da doença
falciforme. Rev Bras Hematol Hemoter. 2010;32:203-8. Doi: 10.1590/S1516-
84842010005000072
41. Kirkham JK, Estepp JH, Weiss MJ, Rashkin SR. Genetic variation and sickle cell
disease severity: A systematic review and meta-analysis. JAMA Netw Open.
2023;6(10):e2337484. Doi: 10.1001/jamanetworkopen.2023.37484
106
42. Onimoe G, Rotz S. Sickle cell disease: a primary care update. Cleve Clin J Med.
2020;87(1):19-27. Doi:10.3949/ccjm.87a.18051
43. Manley AF. Legislation and funding for sickle cell services, 1972-1982. Am J Pediatr
Hematol Oncol [Internet]. 1984 [cited 2024 Jul 25]. Spring;6(1):67-71. Available from:
https://journals.lww.com/jphoonline/abstract/1984/00610/Legislation_and_funding_for_sickle_cell_services,.12.aspx
44. Ministério da Saúde (BR). Portaria nº 1.391/GM, de 16 de agosto de 2005. Institui,
no âmbito do Sistema Único de Saúde - SUS, como diretrizes para a Política Nacional de
Atenção Integral às Pessoas com Doença Falciforme e outras Hemoglobinopatias
[Internet]. Brasília: Ministério da Saúde (BR); 2005 [cited 2023 Dez 12]. Diário Oficial
da União (1391). Available from:
https://bvsms.saude.gov.br/bvs/saudelegis/gm/2005/prt1391_16_08_2005.html
45. Adorno, EV. Como é feito o diagnóstico da doença falciforme? Fiocruz Bahia
[Internet]. 2020 [cited 2024 Aug 8]. Available from:
https://www.youtube.com/watch?v=mMuaYfza-lQ
46. Ministério da Saúde (BR). Portaria nº 822, de 06 de junho de 2001. Institui no âmbito
do Sistema Único de Saúde, o Programa Nacional de Triagem Neonatal / PNTN
[Internet]. Brasília: Ministério da Saúde; 2001 [cited 2024 June 20]. Available from:
http://bvsms.saude.gov.br/bvs/saudelegis/gm/2001/prt0822_06_06_2001.html
47. Ministério da Saúde(BR). Portaria GM/MS nº 1.459, de 24 de junho de 2011. Institui,
no âmbito do Sistema Único de Saúde - SUS - a Rede Cegonha [Internet]. Brasília:
Ministério da Saúde; 2011 [cited 2024 May 15]. Available from:
https://bvsms.saude.gov.br/bvs/saudelegis/gm/2011/prt1459_24_06_2011.html
48. Mason SF, Dasgupta M, Flynn KE, Simpson PM, Singh A. Comparison of CAT and
short forms for PROMIS pain and physical health domains in children with sickle cell
disease. J Patient Rep Outcomes. 2023;7(1):12. Doi: 10.1186/s41687-023-00553-3
49. Al-Samkari H, Van Beers EJ, Morton DH, Eber SW, Chonat S, Kuo KHM, et al.
Health-related quality of life and fatigue in children and adults with pyruvate kinase
deficiency. Blood Adv. 2022;6(6):1844-53. Doi: 10.1182/bloodadvances.2021004675
50. McClish DK, Smith WR, Dahman BA, Levenson JL, Roberts JD, Penberthy LT, et al.
Pain site frequency and location in sickle cell disease: the PiSCES project. Pain. 2009
Sep;145(1-2):246-51. Doi: 10.1016/j.pain.2009.06.029
51. Traoré C, Kyelem CG, Semdé A, Koulidiati J, Sanou AF, Bokoum S, Kafando E.
Prevalence of chronic complications of sickle cell disease at the Bobo-Dioulasso
Teaching Hospital, Burkina Faso. Bull Soc Pathol Exot. 2020;113(1):5-11. Doi:
10.3166/bspe-2020-0112
107
52. Václavů L, Petr J, Petersen ET, Mutsaerts HJMM, Majoie CBL, Wood JC, et al.
Cerebral oxygen metabolism in adults with sickle cell disease. Am J Hematol.
2020;95(4):401-12. Doi: 10.1002/ajh.25727
53. Fox CK, Leykina L, Hills NK, Kwiatkowski JL, Kanter J, Strouse JJ, et al.
Hemorrhagic stroke in children and adults with sickle cell anemia: The Post-STOP
cohort. Stroke. 2022;53(11):e463-e466. Doi:10.1161/STROKEAHA.122.038651
54. Daltro G, Franco BA, Veiga D, Faleiro T, Lima V, Vitório F, et al. Desenvolvimento
de Osteonecrose pós infecção por Covid-19. J Regen Biol Med. 2021;3(5)1-8. Doi:
10.37191/Mapsci-2582-385X-3(5)-087
55. Botelho V L, Silva ICF, Daltro PB, Silva ICF, Guimarães JMM. Prevalence of femoral
head ostenecrosis in patients with falciform anemia: a bibliographic review in pediatrics.
Int J Pediatr Res. 2020;6:064. Doi: 10.23937/2469-5769/1510064
56. Daltro G, Alencar DFD, Sobrinho UB, Guedes A, Fortuna VA. Osteonecrose da
cabeça femoral na anemia falciforme. Gaz méd Bahia. 2010;3:26. Available from:
https://gmbahia.ufba.br/index.php/gmbahia/article/viewFile/1107/1063
57. Miyahara HS, Ranzoni LV, Ejnisman L, Vicente JRN, Croci AT, Gurgel HMC.
Osteonecrosis of the femoral head: Update article. Rev Bras Ortop. 2022;57(3):351-9.
Doi: 10.1055/s-0041-1736308
58. Abbade LPF, Fradeb MAC, Pegasc JRP, Dadalti‐Granjaf P, Garciag LC, Filhoh RB,
et al. Consenso sobre diagnóstico e tratamento das úlceras crônicas de perna – Sociedade
Brasileira de Dermatologia. Anais Brasileiros de Dermatologia. 2020;95:1-18. Doi:
10.1016/j.abdp.2020.06.003
59. Souza VR, Kelly S, Cerdeira Sabino E, Oliveira FM, Silva T, Teixeira CM, et al.
Factors associated with leg ulcers in adults with sickle cell disease in Brazil. Adv Skin
Wound Care. 2023;36(2):98-105. Doi:10.1097/01.ASW.0000911152.41719.e5
60. Halabi-Tawil M, Lionnet F, Girot R, Bachmeyer C, Lévy PP, Aractingi S. Sickle cell
leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol.
2008;158(2):339-44. Doi: 10.1111/j.1365-2133.2007.08323.x
61. Sahu T, Verma HK, Ganguly S, Sinha M, Sinha R. Common, but neglected: A
comprehensive review of leg ulcers in sickle cell disease. Adv Skin Wound Care.
2021;34(8):423-31. Doi: 10.1097/01.ASW.0000755924.12513.40
62. Levenson JL, McClish DK, Dahman BA, Bovbjerg VE, Citero VA, Penberthy LT, et
al. Depression and anxiety in adults with sickle cell disease: the PiSCES project.
Psychosom Med. 2008;70(2):192-6. Doi: 10.1097/PSY.0b013e31815ff5c5
108
63. Al-Marzouki AF, Alrefaie NI, Aljohani NA, Alandanusi RA, Alghamdi AA, Radhwi
OO. The prevalence of depression and anxiety among sickle cell disease patients in King
Abdulaziz University Hospital. Cureus. 2021;29;13(9):e18374. Doi:
10.7759/cureus.18374
64. Araujo Junior JA, Antonelli Rossi DA, Carneiro Valadão TF, Milan-Mattos JC, Catai
AM, Sato TO, et al. Cardiovascular benefits of a home-based exercise program in patients
with sickle cell disease. PLoS One. 2021;16(5):e0250128.
Doi:10.1371/journal.pone.0250128
65. Martin C, Pialoux V, Faes C, Charrin E, Skinner S, Connes P. Does physical activity
increase or decrease the risk of sickle cell disease complications? Br J Sports Med.
2018;52(4):214-8. Doi: 10.1136/bjsports-2015-095317
66. Kazak A, Ozkaraman A. The effect of progressive muscle relaxation exercises on pain
on patients with sickle cell disease: randomized controlled study. Pain Manag Nurs.
2021;22(2):177-83. Doi:10.1016/j.pmn.2020.02.069
67. Zanoni CT, Galvão F, Maria RM, Zulli R, Ricciardi JB, Junior CA, et al. Effectiveness
of a home-based therapeutic exercise program on lower back pain and functionality in
Sickle Cell Disease (SCD) patients. Hematol Transfus Cell Ther. 2021;43(3):268-79.
Doi: 10.1016/j.htct.2020.05.004
68. Carvalho-Siqueira GQ, Ananina G, Souza BB, Borges MG, Ito MT, Silva-Costa SM,
et al. Whole-exome sequencing indicates FLG2 variant associated with leg ulcers in
Brazilian sickle cell anemia patients. Exp Biol Med (Maywood). 2019;244(11):932-9.
Doi:10.1177/1535370219849592
69. Antwi-Boasiako C, Andemariam B, Colombatti R, Asare EV, Strunk C, Piccone CM,
et al. A study of the geographic distribution and associated risk factors of leg ulcers within
an international cohort of sickle cell disease patients: the CASiRe group analysis. Ann
Hematol. 2020;99(9):2073-79. Doi:10.1007/s00277-020-04057-8
70. Mendes RS, Oliveira DB. Equipe multidisciplinar no cuidado à pessoa com doença
falciforme. Hematol Transfus Cell Ther. 2024;46: S1193. Doi:
10.1016/j.htct.2024.09.2087
71. Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, et al.
Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes.
2006;4:59. Doi: 10.1186/1477-7525-4-59
72. Al Zahrani OS, Mukhtar O, Al Subaie M, Al Howiti WE. Systematic psychiatric
assessment of patients with sickle cell disease. Saudi Med J. 2019;40(1):59-65. Doi:
10.15537/smj.2019.1.22919
109
73. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell
disease. J Hematol Oncol Internet. 2022;15(1):20. Doi:10.1186/s13045-022-01237-z
74. Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell
disease: Definition, pathophysiology, and management. Eur J Haematol.
2020;105(3):237-46. Doi:10.1111/ejh.13430
75. Karafin MS, Singavi A, Hussain J, Wandersee N, Heinrich T, Hurley RW, et al.
Predictive factors of daily opioid use and quality of life in adults with sickle cell disease.
Hematology. 2018;23(10):856-63. Doi: 10.1080/10245332.2018.1479997
76. Abrams DI, Couey P, Dixit N, Sagi V, Hagar W, Vichinsky E, et al. Effect of inhaled
cannabis for pain in adults with sickle cell disease: a randomized clinical trial. JAMA
Netw Open. 2020;3(7):e2010874. Doi:10.1001/jamanetworkopen.2020.10874
77. Coleman B, Ellis-Caird H, McGowan J, Benjamin MJ. How sickle cell disease
patients experience, understand and explain their pain: An Interpretative
Phenomenological Analysis study. Br J Health Psychol. 2016;21(1):190-203.
Doi:10.1111/bjhp.12157
78. Secretaria Municipal da Saúde de São Paulo (BR). Linha de cuidados em Doença
Falciforme na Atenção Básica [Internet]. São Paulo: Secretaria Municipal da Saúde de
São Paulo; 2021 [cited 2024 June 12]. Available from:
https://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/Manual_Anemia_Falc
iforme3_14_5_2021.pdf
79. Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J. American
Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood
Adv. 2020;4(2):327-55. Doi:10.1182/bloodadvances.2019001143
80. Lacerda FKL, Ferreira SL, Nascimento ERD, Costa DO, Cordeiro RC. Self-care
deficits in women with leg ulcers and sickle cell disease. Rev Bras Enferm.
2019;72(3):72-8. Doi:10.1590/0034-7167-2018-0005
81. Wonkam A, Mba CZ, Mbanya D, Ngogang J, Ramesar R, Angwafo FF. Psychosocial
stressors of sickle cell disease on adult patients in Cameroon. J Genet Couns.
2014;23:948-56. Doi: 10.1007/s10897-014-9701-z
82. Holdford D, Vendetti N, Sop DM, Johnson S, Smith WR. Indirect economic burden
of sickle cell disease. Value Health. 2021;24(8):1095-101. Doi:
10.1016/j.jval.2021.02.014
83. Oliveira LAB, Lopes TS, Sousa JN, Souza AC, Baptista AF, Sousa HFP, et al.
Religiosity, anxiety, depression, and suicidal ideation in brazilian patients with sickle cell
disease. Reflexus. 2023;17(2):277-90. Doi: 10.20890/reflexus.v17i2.2769
110
84. Darbari DS, Brandow AM. Pain-measurement tools in sickle cell disease: where are
we now? Hematology Am Soc Hematol Educ Program. 2017(1):534-41. Doi:
10.1182/asheducation-2017.1.534
85. Galer BS, Jensen MP. Development and preliminary validation of a pain measure
specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48(2):332-8.
Doi:10.1212/wnl.48.2.332
86. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al.
Comparison of pain syndromes associated with nervous or somatic lesions and
development of a new neuropathic pain diagnostic questionnaire (DN-4). Pain.
2005;114(1-9):29-36. Doi: 10.1016/j.pain.2004.12.010
87. Martinez JEM, Fujiki RHM. Criação e validação de um diário de dor para
acompanhamento de dor musculoesquelética crônica no Conjunto Hospitalar de
Sorocaba. Rev Fac Ciênc Méd Sorocaba. In: 32º Congresso da SUMEP [Internet]; 2015
[cited 2024 Sep 15]. Available from:
http://revistas.pucsp.br/index.php/RFCMS/rt/printerFriendly/24914/0
88. Antunes FD, Silva Junior CL, Cerqueira KS, Faro LM, Cipolotti R. Screening for
neuropathic pain in patients with sickle cell disease: is a single assessment scale
sufficient? Orphanet J Rare Dis. 2019;14(1):108. Doi:10.1186/s13023-019-1082-9
89. Carvalho AB, Garcia JBS, Silva TKM, Ribeiro JVF. Translation and transcultural
adaptation of Pain Quality Assessment Scale (PQAS) to brazilian version. Rev Bras
Anestesiol. 2016;66(1):94-104. Doi: 10.1016/j.bjane.2013.10.018
90. Pimenta CAM; Teixeira, MJ. Questionário de dor McGill: proposta de adaptação para
a língua portuguesa. Rev Esc Enferm USP. 1996;30(3):473-83. Doi:10.1590/S0080-
62341996000300009
91. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the
brief pain inventory for use in documenting the outcomes of patients with noncancer pain.
Clin J Pain. 2004;20(5):309-18. Doi: 10.1097/00002508-200409000-00005
92. Driscoll J, Bamne M, Jonassaint C. Assessing the validity of the brief pain inventory
for use among adults with sickle cell disease. Blood. 2017;130, 5579. Doi:
10.1182/blood.V130.Suppl_1.5579.5579
93. Wilkie DJ, Molokie R, Boyd-Seal D, Suarez MS, Kim JOK, Zong E, et al. Patientreported outcomes: descriptors of nociceptive and neuropathic pain and barriers to
effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc.
2010;102(1):18-27. Doi:10.1016/s0027-9684(15)30471-5
111
94. O'Brien JA, Drake JA, Bearden DJ, Ono KE, Sil S, Cohen LL, et al. Cognitive
considerations for adults with sickle cell disease completing the brief pain inventory. Pain
Rep. 2025;9;10(1):e1189. Doi: 10.1097/PR9.0000000000001189
95. Zempsky WT, Stevens MC, Santanelli JP, Gaynor AM, Khadka S. Altered functional
connectivity in sickle cell disease exists at rest and during acute pain challenge. Clin J
Pain. 2017;33(12):1060-70. Doi:10.1097/AJP.0000000000000492
96. Vitorino CF, Silva NCOV, Alfieri FM. Utilização da algometria e termografia
infravermelha como instrumentos de avaliação da dor: uma revisão sistemática. Acta
Fisiátr. 2023;30(2):129-35. Doi: 10.11606/issn.23170190.v30i2a1782378
97. Oliveira NC, Silva KR, Santos AC, Alfieri FM. Reproducibility and reliability of
pressure algometry: are digital and analogue devices comparable?. BrJP.
2024;7:e20240055. Doi: 10.5935/2595-0118.20240055-en
98. Lima KTLL, Pereira JOF, Reis PRM, Alcântara KC, Rodrigues FM. Quality of life
of sickle cell disease carriers. J Nurs. 2019;13(2):424-30. Doi: 10.5205/1981-8963-
v13i02a237424p424-430-2019
99. Ohara DG, Ruas G, Castro SS, Martins PR, Walsh IA. Musculoskeletal pain, profile
and quality of life of individuals with sickle cell disease. Rev Bras Fisioter.
2012;16(5):431-8. Doi:10.1590/s1413-35552012005000043
100. Al Jaouni SK, Al Muhayawi MS, Halawa TF, Al Mehayawi MS. Treatment
adherence and quality of life outcomes in patients with sickle cell disease. Saudi Med J
[Internet]. 2013 [cited 2024 Nov 23].;34(3):261-265. Available from:
https://smj.org.sa/content/smj/34/3/261.full.pdf
101. Connolly ME, Bills SE, Hardy SJ. Neurocognitive and psychological effects of
persistent pain in pediatric sickle cell disease. Pediatr Blood Cancer. 2019;66(9):e27823.
Doi:10.1002/pbc.27823
102. Leite MM, Santos MEFD, Fernandes JVA, Geovanini DR, Soares FC, Fonseca TCC,
et al. Depressão em pacientes com doença falciforme: uma revisão de literatura. Hematol
Transfus Cell Ther. 2024;46, S1139. Doi: 10.1016/j.htct.2024.09.1991
103. Castro MMC, Quarantini L, Batista-Neves S, Kraychete DC, Daltro C, MirandaScippa Â. Validade da escala hospitalar de ansiedade e depressão em pessoas com dor
crônica. Rev Bras Anestesiol. 2006;56(5):470-7. Doi: 10.1590/S0034-
70942006000500005
104. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. PROMIS
Cooperative Group. The Patient-Reported Outcomes Measurement Information System
(PROMIS) developed and tested its first wave of adult self-reported health outcome item
112
banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179-94. Doi:
10.1016/j.jclinepi.2010.04.011
105. Ameringer S, Elswick RK Jr, Menzies V, Robins JL, Starkweather A, Walter J, et
al. Psychometric evaluation of the patient-reported outcomes measurement information
system fatigue-short form across diverse populations. Nurs Res. 2016;65(4):279-89. Doi:
10.1097/NNR.0000000000000162
106. Silva WS, Lopes TDSL, Reis DS, Barreto DPS, Silva GS, Oliveira TWS. Aspectos
sociodemográficos e clínicos de pacientes com doenças falciformes dos centros de
referência em Salvador, Bahia. BJHR. 2022;5(3):10526-39. Doi: 10.34119/bjhrv5n3-215
107. Fortunato JG, Furtado MS, Assis Hirabae LF, Oliveira JA. Escalas de dor no
paciente crítico: uma revisão integrativa. Revista HUPE. 2013;12(3):110-7.
Doi:10.12957/rhupe.2013.7538
108. Azevedo LF, et al. Tradução, adaptação cultural e estudo multicêntrico de validação
de instrumentos para rastreio e avaliação do impacto da dor Crónica. IN: Dor®
Questionários sobre Dor Crónica. Permanyer Portugal: APED – Associação Portuguesa
para o Estudo da Dor [Internet]. 2007 [cited 2024 Dec 26];5(4):6-39. Avaiable from:
https://www.aped-dor.org/socios/material_bibliografico/diversos_Questionarios_DorRev_DOR_Volume15-n4-2007.pdf
109. Toledo FO. Adaptação cultural do inventário breve da dor para a língua portuguesa
no Brasil e teste de suas propriedades psicométricas [Internet]. 2008 [cited 2024 dez 22
]. Dissertação (Mestrado) – Universidade de São Paulo, Ribeirão Preto. Available from:
https://repositorio.usp.br/item/001655448
110. Ware Jr JE, Sherbourne CD. The MOS 36-ltem short-form health survey (SF-36): I.
Conceptual framework and item selection. Medical care [Internet]. 1992 [cited 2024 Dec
19];30(6), 473-83. Available from: https://journals.lww.com/lwwmedicalcare/abstract/1992/06000/The_MOS_36_ltem_Short_Form_Health_Survey__S
F_36__.2.aspx
111. Ware JE, Snow KK, Kosinski M, Gandek B. Manual e interpretação da pesquisa de
saúde SF-36 [Internet]. 1993 [cited 2024 oct 16]. Available from:
https://www.researchgate.net/profile/John-Ware-6/publication/313050850_SF36_Health_Survey_Manual_Interpretation_Guide/links/594a5b83aca2723195de5c3d/S
F-36-Health-Survey-Manual-Interpretation-Guide.pdf
112. Botega NJ, Bio MR, Zomignani MA, Garcia Jr C, Pereira WAB. Transtornos do
humor em enfermaria de clínica médica e validação de escala de medida (HAD) de
ansiedade e depressão. Rev Saúde Pública. 1995;29(5):359-63. Doi: 10.1590/S0034-
89101995000500004
113
113. Alves FSM, Pinto RDMC, Mendonça TMS, Silva CHMD. Tradução e adaptação
transcultural do domínio fadiga do Patient-Reported-Outcomes Measurement
Information System (PROMIS) para a língua portuguesa. Cad Saúde Pública.
2014;30(5):1103-10. Doi: 10.1590/0102-311X00104513
114. Promis. Manual de pontuação de fadiga PROMIS. 2021[Internet]. National Institutes
of Health (NIH) [cited 2024 oct 16]. Available from:
https://www.healthmeasures.net/images/PROMIS/manuals/Scoring_Manuals_/PROMIS
_Fatigue_Scoring_Manual.pdf
115. R Core Team (2024). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria
116. Dodo R, Zohoun A, Baglo T, Mehou J, Anani L. Emergency treatment of sickle cell
diseases in the Blood Diseases Department at the Koutoukou Maga National Teaching
Hospital, Cotonou, Benin. Pan Afr Med J. 2018;30:192. Doi:
10.11604/pamj.2018.30.192.15931118
117. Gioseffi JR, Simão FCDS, Melo NVM, Fróes E, Fedozzi F, Pinto CMF, Loggetto
SR. Panorama da doença falciforme no Brasil (2012 A 2022). Hematol Transfus Cell
Ther. 2024;46(4):S29. Doi: 10.1016/j.htct.2024.09.049
118. Myrvik MP, Drendel AL, Brandow AM, Yan K, Hoffmann RG, Panepinto JA. A
comparison of pain assessment measures in pediatric sickle cell disease: visual analog
scale versus numeric rating scale. J Pediatr Hematol Oncol. 2015;37(3):190-4. Doi:
10.1097/MPH.0000000000000306
119. Leão Lima KTL, Ferreira Pereira JO, Melo Reis PR, Correia de Alcântara K, Melo
Rodrigues F. Qualidade de vida dos portadores de doença falciforme. Rev enferm UFPE
on line. 2019;13(2): 424-30. Doi: 10.5205/1981-8963-v13i02a237424p424-430-2019
120. Bulgin D, Douglas C, Tanabe P. A pilot test of the adult sickle cell Quality of
Life Measurement Information System (ASCQ-Me) and the Jenerette Self-Care
Assessment (J-SAT) Tools in adults with sickle cell disease. Pilot Feasibility Stud.
2019;5(85):1-7. Doi:10.1186/s40814-019-0471-0
121. Olowoselu FO, Uche E, Oyedeji OA, Enabulele O, Ogunnubi OP, Olowoselu OI, et
al. Anxiety and depression in sickle cell anaemia: the impact of pain in a Nigerian
population. Nigerian Hospital Practice [Internet]. 2021 [cited 2024 Dec 28];27(1-2), 8-
14. Available from: https://www.ajol.info/index.php/nhp/issue/view/19571
122. Ameringer S, Elswick RK Jr, Smith W. Fatigue in adolescents and young adults with
sickle cell disease: biological and behavioral correlates and health-related quality of life.
J Pediatr Oncol Nurs. 2014;31(1):6-17. Doi: 10.1177/1043454213514632 | pt_BR |